Author Archives: Pharm Exec

Indonesia “Most Promising” Emerging Market in 2015

Indonesia is expected to be the most promising market for pharma next year, thanks to its new healthcare insurance scheme Jaminan Kesehatan Nasional (JKN), according to Reenita Das, partner and senior vice president of Healthcare & Life Sciences at Frost & Sullivan.
Posted in Emerging Markets, Global, Op-Ed | Tagged , , , , , | Leave a comment

Biotech Professionals and Drug Manufacturers Targeted by Latest Cyber Threat

By Randi Hernandez. The New York Times (NYT) reported on Dec. 1, 2014 that companies in the biotechnology sector might be the latest victims of computer security breaches. The perpetrators, who are thought to be former investment bankers, are using the information they glean to obtain a market edge on the pharmaceutical industry.
Posted in Biotech | Tagged , | Leave a comment

Shire to Relocate More Than 500 Jobs to Lexington, MA

Shire plans to relocate more than 500 positions to Massachusetts from its Chesterbrook, PA, site and establish Lexington, MA, as the company’s US operational headquarters. The transition is a continuation of the company’s “One Shire” efficiency program and will streamline business globally through two principal locations—Massachusetts and Switzerland—with support from a limited number of regional […]
Posted in Strategy | Tagged , | Leave a comment

EMA Revises Conflict-of-Interest Policy

The European Medicines Agency (EMA) has published its revised policy on handling declarations of interests for scientific-committee members and experts. The revisions strive for a more balanced approach in restricting the involvement of experts with possible conflicts of interests in the Agency’s work, while maintaining access to expertise.
Posted in compliance, Europe, Regulatory | Tagged , , , , | Leave a comment

Pharma Showing Signs of Stability Despite Patent Cliffs

The pharmaceutical market is beginning to show signs of stability, with a review of 30 leading companies highlighting combined revenues of $718.7 billion in 2013, down just 0.2% from 2012, according to GlobalData.
Posted in Deals, Strategy | Tagged , , , , , , | Leave a comment
  • Categories

  • Meta